CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/1b Trial of AB801 in Combination With Chemotherapy and PD-1/PD-L1 Blockade in Patients With Cholangiocarcinoma or Pancreatic Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07619313
Title field or adapter rule: {'original_value': 'A Phase 1/1b Trial of AB801 in Combination With Chemotherapy and PD-1/PD-L1 Blockade in Patients With Cholangiocarcinoma or Pancreatic Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:27.169164+00:00
Published At: 2026-08-20T00:00:00+00:00
Record Updated At: 2026-08-20
Source Retrieved At: 2026-10-31T22:17:58.991924+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Borderline Resectable Pancreatic Ductal Adenocarcinoma", "Locally Advanced Cholangiocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Cholangiocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-08-20", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07619313"
protocolSection.identificationModule.officialTitle: "A Phase 1/1b Trial of AB801 in Combination With Chemotherapy and PD-1/PD-L1 Blockade in Patients With Cholangiocarcinoma or Pancreatic Adenocarcinoma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Cohort I (AB801, gemcitabine, cisplatin, durvalumab)', 'Cohort II (AB801, zimberelimab, FOLFIRINOX)'], 'description': 'Undergo tissue biopsy', 'name': 'Biopsy Procedure', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort I (AB801, gemcitabine, cisplatin, durvalumab)'], 'description': 'Given IV', 'name': 'Cisplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort I (AB801, gemcitabine, cisplatin, durvalumab)', 'Cohort II (AB801, zimberelimab, FOLFIRINOX)'], 'description': 'Undergo CT', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort I (AB801, gemcitabine, cisplatin, durvalumab)'], 'description': 'Given IV', 'name': 'Durvalumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort II (AB801, zimberelimab, FOLFIRINOX)'], 'description': 'Given IV', 'name': 'Fluorouracil', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort I (AB801, gemcitabine, cisplatin, durvalumab)'], 'description': 'Given IV', 'name': 'Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort II (AB801, zimberelimab, FOLFIRINOX)'], 'description': 'Given IV', 'name': 'Irinotecan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort II (AB801, zimberelimab, FOLFIRINOX)'], 'description': 'Given IV', 'name': 'Leucovorin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort I (AB801, gemcitabine, cisplatin, durvalumab)', 'Cohort II (AB801, zimberelimab, FOLFIRINOX)'], 'description': 'Given PO', 'name': 'Ligritinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort I (AB801, gemcitabine, cisplatin, durvalumab)', 'Cohort II (AB801, zimberelimab, FOLFIRINOX)'], 'description': 'Undergo MRI', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort II (AB801, zimberelimab, FOLFIRINOX)'], 'description': 'Given IV', 'name': 'Oxaliplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort II (AB801, zimberelimab, FOLFIRINOX)'], 'description': 'Give IV', 'name': 'Zimberelimab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.